We are pleased to announce that the interim report for the first quarter of 2025 has been published. During this period, the company generated revenues of PLN 1,114,139.91, while significantly reducing operating costs. As a result, profitability improved significantly – EBITDA amounted to PLN 14,093.45, which represents a positive result at this level compared to the loss recorded in the same period of the previous year.

During the period under review, Proacta focused on the further development of the Dbam o Siebie platform, both in terms of technology and sales and marketing. The increase in user efficiency and engagement confirms the effectiveness of the strategy implemented.

In addition, the Company has secured new contracts and partnerships, including with the Bank Guarantee Fund, and has signed an agreement with the Medical Research Agency, which will have a significant impact on the further development of bioinformatics projects. In the opinion of the Management Board, these activities will have a positive impact on subsequent financial periods as early as 2025.

The full text of the report is available in the Investor Relations tab.

We are pleased to announce that on April 15, 2025, Proacta SA signed a letter of intent with the Medical University of Łódź, one of the most renowned academic institutions in Poland. The purpose of the signed document is to establish cooperation in the field of creating concepts and implementing projects based on the analysis of medical data and the construction of analytical and predictive models using artificial intelligence.

The cooperation also includes the exchange of knowledge and expert experience. Proacta SA has ready-made solutions and advanced technological infrastructure, including its own Data Center dedicated to the analysis of medical and genetic data, which creates a solid foundation for joint research and development activities.

The letter of intent is a declaration of intent to cooperate, without creating binding obligations, and the details of individual initiatives will be regulated in separate agreements.

The Management Board of Proacta SA decided to publish this information, bearing in mind the potentially significant impact of the agreement on the development of modern services in the area of e-health and the strengthening of the company’s position and recognition in the healthcare sector, which, in the opinion of the Management Board, may translate into the economic situation of Proacta SA in the future.

We are delighted to announce that Proacta SA has won an important tender for the maintenance of the key system of the Bank Guarantee Fund (BFG). This strategic project confirms our strong position in the IT sector and our competence in managing systems critical to financial institutions.

Under the agreement, our company will provide comprehensive support, maintenance, and development of the key BFG system, which is responsible for the financial security of bank customers. Thanks to this project, Proacta SA not only strengthens its reputation as a reliable technology partner, but also confirms its commitment to the highest standards of quality and security.

We are confident that our experience and professionalism will contribute to the continued success of both parties.
More details on the project will be available soon!

The Management Board of Proacta SA, based in Warsaw, announces that on April 8, it received official notification of the outcome of the public procurement procedure for the “Purchase of Guarantee System Maintenance (SRG) services, together with the provision of other services and supplies” for the Bank Guarantee Fund. In the proceedings in question, the most advantageous bid, submitted by a consortium consisting of Euvic SA and Proacta SA, was selected.
Value of the consortium’s bid: PLN 17,478,755.39
Proacta’s share in the consortium’s remuneration for the performance of the task will be 98%.

The subject of the proceedings was to select a contractor for the key task of maintaining and developing one of the basic systems of the Bank Guarantee Fund. According to the order, the task is to be completed within four years.

The signing of this agreement will confirm the Company’s fruitful cooperation to date and ensure stable and regular revenues in the long term. This is an important step for us in strengthening our market position and building lasting relationships with key partners.

The selection of our consortium’s bid is also a measurable and positive effect of the synergy and effective cooperation between Proacta SA and Euvic SA. As announced by the President of the Management Board of Proacta in his earlier statements, this cooperation brings tangible benefits and opens up new opportunities for development.

We are proud to announce that Paweł Ciesielka, CEO of Proacta SA, gave an interview to MamBiznes.pl, in which he talked about the future of medicine supported by artificial intelligence and our company’s unique bioinformatics expertise.

During the conversation, he emphasized that the development of advanced AI algorithms in medical data analysis opens up new diagnostic and therapeutic possibilities. Our proprietary artificial intelligence models support doctors and patients, helping them make faster and more accurate decisions.

Thanks to our interdisciplinary team of specialists and the use of modern technologies, we create solutions that have a real impact on the quality of healthcare.

The full interview is available here: Link to the article